logo-loader
Cynata Therapeutics Ltd

Cynata Therapeutics’ market-disruptive regenerative medicines complete world-first trial

Killian Kelly, vice president product development at Cynata Therapeutics Ltd (ASX:CYP), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney.

Cynata Therapeutics has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute graft-versus-host disease (GvHD). The biotech company reported it had achieved a world first with the trial completion.

Quick facts: Cynata Therapeutics Ltd

Price: $1.60

Market: ASX
Market Cap: $164.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Northern Minerals reveals talks with US government agencies,...

Northern Minerals Ltd (ASX:NTU) CEO George Bauk tells Proactive he recently met US government agencies, who he says wanted to get a better sense of the Australian company's progress with its dysprosium production, and its strategy going forward. Bauk is currently in New York meeting with...

2 days, 9 hours ago

2 min read